CClinicalTrials.gg
Sign In
TerminatedNCT03606070IMAHTEPUpdated Aug 19, 2026

Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study

An interventional study of PET-MRI in NSCLC, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Not applicable, Interventional, and Diagnostic

Why this study was terminated
Lack of inclusion

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Nov 2017, registered Jul 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

To estimate the intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping in locally advanced and trace mestastatic non-small cell lung cancer (NSCLC).

02

Conditions studied

  • NSCLC
03

In context

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris is the lead sponsor of 242 studies on the registry; 65 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Locally advanced NSCLC (stages IIB, IIIA or IIIB of the TNM classification 7th edition) or trace metastatic stage IV (\</=5 mestastasis, \</= 3 organ reached)
  2. Exclusive therapeutic management by concomitant radio-chemotherapy administered in accordance with international recommendations (dual therapy with platinum salts)
  3. Signed consent
  4. Patients affiliated with the social security scheme or beneficiary of a similar scheme.

Exclusion criteria

Exclusion Criteria:

  1. Minor
  2. Pregnant / lactating woman
  3. Person deprived of liberty by judicial or administrative decision, adults who are the subject of a legal protection measure or unable to express their consent
  4. Previous cancer in the 2 years prior to registration
  5. Previousradiotherapy / thoracic surgery
  6. Patients under experimental treatment or for whom the administration of an experimental treatment is planned
  7. Claustrophobic patients
  8. Severe Renal Insufficiency (Clearance MDRD Cockroft \<30ml / min)
  9. Uncontrolled diabetes, hyperglycemia> 1.8g / L
  10. Patient with metallic implants not compatible with MRI or any immovable implanted electronic medical device (eg pacemaker, neurostimulator, cochlear implants, etc.)
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Other
    Patients with NSCLC

    Characterization of tumor heterogeneity by multiparametric regional mapping PET-MRI. Patients will realize: * a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI) * a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI).

    Diagnostic Test: PET-MRI

Interventions

  • Diagnostic testPET-MRI

    * a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI) * a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI).

06

What researchers measure

Primary outcomes

  1. Measurement of intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping performed before and under treatment.

    Time frame: Up to 24 months

07

Study locations

1 site
  • Gustave Roussy
    Villejuif, Val de Marne 94805, France
08

References and documents

Publications

  • Besson FL, Fernandez B, Faure S, Mercier O, Seferian A, Mignard X, Mussot S, le Pechoux C, Caramella C, Botticella A, Levy A, Parent F, Bulifon S, Montani D, Mitilian D, Fadel E, Planchard D, Besse B, Ghigna-Bellinzoni MR, Comtat C, Lebon V, Durand E. 18F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data. EJNMMI Res. 2020 Jul 30;10(1):88. doi: 10.1186/s13550-020-00671-9. PubMed 32734484 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03606070
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Responsible party
Sponsor
First posted
Jul 30, 2018
Start date
Nov 25, 2017
Primary completion
Aug 29, 2019
Completion
Aug 29, 2019
Last update
Aug 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Start the discussion